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Homeostatic plasticity keeps neuronal spiking output
within an optimal range in the face of chronically al-
tered levels of network activity. Little is known about
the underlying molecular mechanisms, particularly in
response to elevated activity. We report that, in
hippocampal neurons experiencing heightened ac-
tivity, the activity-inducible protein kinase Polo-like
kinase 2 (Plk2, also known as SNK) was required
for synaptic scaling—aprincipalmechanismunderly-
ing homeostatic plasticity. Synaptic scaling also re-
quired CDK5, which acted as a ‘‘priming’’ kinase for
the phospho-dependent binding of Plk2 to its sub-
strate SPAR, a postsynapticRapGAPandscaffolding
molecule that is degraded following phosphorylation
by Plk2. RNAi knockdown of SPARweakened synap-
ses, and overexpression of a SPAR mutant resistant
to Plk2-dependent degradation prevented synaptic
scaling. Thus, priming phosphorylation of the Plk2
binding site in SPAR by CDK5, followed by Plk2
recruitment andSPARphosphorylation-degradation,
constitutes amolecular pathway for neuronal homeo-
static plasticity during chronically elevated activity.
INTRODUCTION
Long-term potentiation (LTP) and long-term depression (LTD) are
examples of Hebbian-type synaptic plasticity, in which corre-
lated patterns of activity in pre- and postsynaptic neurons lead
to long-term changes in the strength of their connections. How-
ever, the same mechanisms could also result in runaway excita-
tion or depression of neurons. Homeostatic regulation of synap-
tic strength, such as ‘‘synaptic scaling,’’ is generally invoked to
prevent such positive-feedback destabilization. Homeostatic
mechanisms provide compensatory negative feedback through
modulation of global synaptic efficacy and membrane excitabil-
ity to ensure that neurons remain within a suitable operating
range of spiking activity (Burrone and Murthy, 2003; Davis,
2006; Turrigiano, 2007). Despite the presumed importance of
synaptic homeostasis, little is known about the molecular mech-anisms involved in either sensing perturbations from the neu-
ron’s operating range or in executing the negative-feedback con-
trol. Some progress has been achieved in understanding the
homeostatic response to chronic inactivity (e.g., TTX) (Goddard
et al., 2007; Gong et al., 2007; Shepherd et al., 2006; Stellwagen
and Malenka, 2006; Thiagarajan et al., 2006, 2002), but almost
nothing is known about the mechanisms that mediate the adap-
tation to chronically elevated activity.
Activity-dependent changes in gene expression are likely to be
important for the homeostatic response. Indeed, changes in
neuronal activity induced by drug administration (Bui et al.,
2006; Hevroni et al., 1998; Nedivi et al., 1993; Qian et al., 1993;
Yamagata et al., 1993), genetic manipulation (Guan et al.,
2005), or sensory deprivation (Majdan and Shatz, 2006; Tropea
et al., 2006) affect transcription of numerous genes in both mam-
mals and flies. One activity-regulated gene is Polo-like kinase 2
(plk2; also known as serum-inducible kinase [snk]), a member
of the polo family of serine/threonine protein kinases (Kausel-
mann et al., 1999; Ma et al., 2003b; Simmons et al., 1992).
Polo-like kinases (Plks) contain a C-terminal Polo-box domain
(PBD) that mediates autoinhibition of kinase activity as well as
phosphorylation-dependent binding to substrates and docking
proteins (Elia et al., 2003b; Lowery et al., 2004). Although the
closely related kinases Plk1 and Plk3 are critical regulators of
the cell cycle (for review, see van de Weerdt and Medema,
2006), Plk2 seems to have a limited role in cell division (Ma
et al., 2003a). On the other hand, Plk2 mRNA and protein levels
are induced in postmitotic neurons by synaptic activity on the
timescale of hours (Kauselmann et al., 1999; Pak and Sheng,
2003).
Recently, it was revealed that the PBD acts as a phospho-pep-
tide-binding domain with preference for peptides that contain the
consensus sequence [Ser]-[phospho-Ser/phospho-Thr]-[Pro]
(Elia et al., 2003a, 2003b). By phosphorylating such S-S/T-P
sequences, proline-directed kinases like CDKs (cyclin-depen-
dent kinases) and MAP kinases could act as ‘‘priming’’ kinases
to generate PBD-binding sites, thereby recruiting Plks to specific
substrates and docking proteins. Indeed, several recent reports
have found evidence for such priming kinase activity in the regu-
lation of Plk function in the cell cycle. For example, cdc2/CDK1
acts as priming kinase to promote the interaction of Plk1 with
the centrosome protein Cep55 (Fabbro et al., 2005) and the kinet-
ochore-associated protein Bub1 (Qi et al., 2006).Neuron 58, 571–583, May 22, 2008 ª2008 Elsevier Inc. 571
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CDK5 and Plk2 in Synaptic ScalingWhat is the role of Plk2 in neurons? One action seems to be the
phosphorylation and degradation of spine associated RapGAP
(SPAR), a protein of the postsynaptic density (PSD) that interacts
with PSD-95 (Pak and Sheng, 2003; Pak et al., 2001). The phys-
iological function of SPAR is undetermined, but SPAR promotes
the growth of dendritic spines, the postsynaptic compartment of
excitatory synapses, at least in part by inhibiting postsynaptic
Rap signaling (Pak et al., 2001). Plk2 itself seems to be important
for the regulation of spines, as its overexpression causes deple-
tion of mature mushroom spines and the overgrowth of thin,
filopodia-like spines (Pak and Sheng, 2003).
In this study, we identify a critical role for Plk2 in homeostatic
dampening of quantal amplitude (‘‘synaptic scaling’’). CDK5 was
also required for synaptic scaling and acted as priming kinase for
the phospho-dependent binding between Plk2 and its substrate,
SPAR, which promoted Plk2-dependent SPAR degradation.
RNAi knockdown of SPAR expression weakened synapses,
and overexpression of a SPAR mutant resistant to Plk2 degrada-
tion prevented synaptic scaling. Thus, priming phosphorylation
of SPAR by CDK5 and subsequent degradation of SPAR by
activity-induced Plk2 is an important mechanism of homeostatic
plasticity in response to elevated activity.
RESULTS
Plk2 Is Required for Synaptic Scaling and Sufficient
to Weaken Synapses
Plk2 protein is induced over a time course of hours during pe-
riods of high activity in neurons (Kauselmann et al., 1999; Pak
and Sheng, 2003). To investigate the functional significance of
Plk2, we made a dominant interfering construct consisting of
the C-terminal Plk2-PBD fused to GFP. Because the PBD is crit-
ical for proper targeting and functioning of Plks during the cell
cycle (Lowery et al., 2004), the Plk2-PBD overexpressed in neu-
rons should block endogenous Plk2 function by competing for
PBD-binding sites on Plk2 targets and substrates. Plk1-PBD
and Plk3-PBD constructs have been used to dominantly inter-
fere with endogenous Plk1 and Plk3 function (Jiang et al.,
2006; Seong et al., 2002).
We transfected GFP-tagged Plk2-PBD (‘‘GFP-PBD’’) into cul-
tured hippocampal neurons at 16–19 days in vitro (DIV16–19)
and analyzed the effects on AMPA receptor (AMPAR)-mediated
miniature excitatory postsynaptic currents (mEPSCs; measured
in the presence of TTX) 3 days later. To increase network activity
and induce endogenous Plk2 expression, cultures were treated
for 48 hr with the GABAA receptor antagonist picrotoxin (PTX,
100 mM), which causes robust induction of Plk2 expression
(Pak and Sheng, 2003). In mock-treated cultures, GFP-PBD
overexpression had no significant effect on mEPSC amplitude
relative to untransfected or GFP-transfected cells (compare ‘‘ve-
hicle’’ in Figures 1A–1F, summarized in 1G and 1H)—perhaps not
surprising given that Plk2 is expressed at low levels in unstimu-
lated cultures (Pak and Sheng, 2003). In untransfected and
GFP-transfected cells, treatment with PTX resulted in a broad
shift in the cumulative distribution of mEPSC amplitudes
toward lower values (Figures 1A–1D), consistent with ‘‘synaptic
scaling’’ (Turrigiano, 2007; Turrigiano et al., 1998). This leftward
shift toward smaller mEPSC amplitudes was prevented in572 Neuron 58, 571–583, May 22, 2008 ª2008 Elsevier Inc.GFP-PBD-transfected cells; the latter cells actually exhibited
a shift toward larger mEPSCs when treated with PTX (Figures
1E and 1F). Average mEPSC amplitude was significantly re-
duced by PTX in untransfected and GFP-transfected cells, but
not in neurons transfected with the dominant-negative GFP-
PBD construct (Figure 1G). These results indicate that Plk2 is re-
quired for downward scaling of mEPSC amplitude during chron-
ically elevated activity.
We next used a plasmid (pSUPER)-based RNA interference
(RNAi) construct (Brummelkamp et al., 2002) to suppress
expression of endogenous Plk2 (see Figure S1 available online
and Figures 1I and 1J). Following treatment with PTX (48 hr), hip-
pocampal neurons transfected with a control hairpin (scrambled
sequence) for 3–4 days showed a decrease in mean mEPSC
amplitude comparable in degree to untransfected cells and con-
sistent with synaptic scaling (Figure 1K). RNAi knockdown of
Plk2, however, prevented the reduction of mEPSC amplitude
after 48 hr PTX (Figures 1I–1K). Similar to GFP-PBD, Plk2 RNAi
did not affect basal mEPSC size in the absence of PTX treatment
(Figure 1K). The RNAi results corroborate the dominant-negative
GFP-PBD findings, showing that Plk2 is required for synaptic
scaling of quantal amplitude in response to elevated activity.
In untransfected neurons and in neurons transfected with
scrambled RNAi construct or GFP, there was a trend toward de-
creased mEPSC frequency following 48 hr PTX treatment, but
this did not reach statistical significance (Figure 1L). Neither
GFP-PBD nor Plk2 RNAi significantly affected mEPSC frequency
in basal or PTX conditions relative to untransfected cells
(Figure 1L). For these manipulations and those described below,
whole-cell capacitances, series resistances, holding currents,
mEPSC rise times, and membrane resistances were similar
between conditions (Table S1).
We also recorded mEPSCs from cells infected at low titer with
Sindbis virus driving expression of wild-type Plk2 (Figures 1M–
1O). Compared to control GFP-infected cells, neurons infected
with Plk2 and GFP showed a significant drop in mEPSC ampli-
tude. Thus, overexpression of Plk2 is sufficient to weaken
synapses.
Phospho-Dependent Binding of Plk2 to SPAR
Precise regulation of subcellular localization is an important
mechanism for controlling Plk1 function during cell division (van
de Weerdt and Medema, 2006). How might Plk2 be recruited to
key target proteins during synaptic homeostasis and how is this
recruitment regulated? Plk2 binds via its PBD to the Act2 domain
of SPAR, a PSD-95-binding RapGAP enriched in PSDs and
dendritic spines (Pak and Sheng, 2003; Pak et al., 2001). Thus,
the interaction of Plk2 and SPAR could be one mechanism for
targeting Plk2 to postsynaptic sites in neurons. The consensus
binding sequence of the PBD contains the core motif -S-S/T-P-,
where the central serine or threonine is phosphorylated (Elia et al.,
2003b). The -S-S/T-P- sequence is found three times in the Act2
domain of SPAR, with a central serine located at positions 1328,
1384, and 1422 (Figure 2A). Alanine substitution of ser-1328 or
the neighboring ser-1327 eliminated interaction between the
SPAR-Act2 domain and Plk2-PBD, as measured in yeast two-
hybrid assays. Alanine substitution of ser-1383 or ser-1421 had
no effect in the same assay (Figure 2B). Conversely, a single-point
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CDK5 and Plk2 in Synaptic ScalingFigure 1. Plk2 Is Required for Synaptic Scaling during Increased Network Activity and Is Sufficient to Dampen Synaptic Strength
(A–F) Sample traces and cumulative distributions. Representative 5 s long sample traces and average mEPSC event traces were taken from individual untrans-
fected cells or cells transfected with GFP or GFP-PBD and treated with either vehicle (DMSO) or PTX (100 mM) for 48 hr, as indicated. Cumulative distribution plots
were assembled from the first 100 events from each cell recorded (number of cells as in [G]); p < 0.001 (B, D, and F), Kolmogorov-Smirnov test.
(G) Quantification of mean mEPSC amplitude (mean ± SEM) from (A)–(F). n = 10 cells per condition, *p < 0.05, Mann Whitney test.
(H) Cumulative distribution of mEPSC amplitudes from neurons that were untransfected or transfected with GFP or GFP-PBD and treated with vehicle; p > 0.05,
Kolmogorov-Smirnov test.
(I and J) Sample traces and cumulative distribution of mEPSC amplitude from cells transfected with Plk2 RNAi; p > 0.05, Kolmogorov-Smirnov test.
(K) Quantification of mEPSC amplitude (mean ± SEM) from RNAi-transfected neurons. n = 9–11 cells per condition, *p < 0.05, **p < 0.01, Mann Whitney test.
(L) Quantification of mEPSC frequency (mean ± SEM) from neurons transfected as indicated. Neither PTX treatment nor transfection has a significant effect on
minifrequency, one-way ANOVA.
(M–O) Sample traces, cumulative distribution, and quantification of mEPSC amplitude (mean ± SEM) from cells infected at low titer (50–100 cells infected/
15 mm coverslip) with sindbis virus driving expression of either GFP (‘‘GFP’’) or GFP + Plk2 (‘‘Plk2’’). mEPSC recordings were performed 24 hr after infection.
n = 14 cells per condition, **p < 0.01, Mann Whitney test; p < 0.001, Kolmogorov-Smirnov test.mutation at trp-504 of Plk2, a highly conserved residue of the PBD
critical for association with Plk-binding sites (Elia et al., 2003b),
abolished binding to SPAR-Act2 (Figure 2B). None of theseAct2 mutations affected binding of the SPAR-Act2 domain to
a-actinin2, another binding partner of SPAR (D.P.S. and
D.T.S.P., unpublished data) (Figure 2B).Neuron 58, 571–583, May 22, 2008 ª2008 Elsevier Inc. 573
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CDK5 and Plk2 in Synaptic ScalingFigure 2. Plk2-PBD Binds to Canonical PBD
Binding Site in SPAR
(A) Domain organization of Plk2 and SPAR pro-
teins. Candidate Plk2-PBD-binding sites (SSP)
within Act2 domain of SPAR are underlined.
pS1328 and S1328 peptide sequences used in
(D) are highlighted in gray.
(B) Interaction of the Plk2-PBD (PBD) with
SPAR-Act2 and Act2 mutants in yeast two-hybrid
system. a-actinin, PSD-95, and Kv1.4 are positive
controls. pGAD and pBHA are empty vector nega-
tive controls.
(C) Glutathione S-transferase (GST)-PBD pull-
down of myc-tagged SPAR and myc-tagged
SPAR mutants. Extracts of HEK293 cells trans-
fected with myc-tagged SPAR or indicated
SPAR mutants were incubated with gluta-
thione Sepharose beads coupled to GST alone,
GST-PBD(W504F), or GST-PBD, as indicated.
Bound proteins were immunoblotted for myc.
Lane 1 was loaded with 0.5% of the input.
(D) Binding of GST-PBD to phosphorylated ser-
1328 peptide (pS1328). pS1328 and nonphos-
phorylated S1328 peptides were coupled to aga-
rose beads and incubated with extracts from
bacteria expressing GST-PBD. Bound proteins
were analyzed by Coomassie blue staining or
immunoblotting with GST antibodies. Input lane,
10% of extract loaded onto beads.In ‘‘pull-down’’ experiments, a GST fusion protein of Plk20s
PBD (GST-PBD) precipitated full-length wild-type SPAR ex-
pressed in HEK293 cells, but not mutant SPAR in which ser-
1328 was changed to alanine [SPAR(S1328A)] (Figure 2C, lane
4). GST-PBD also precipitated full-length SPAR(S1384A) (lane4),
while GST and GST-PBD(W504F) failed to pull down any of the
SPAR constructs (Figure 2C, lanes 2–3). Thus, the -S-S-P- motif
centered on ser-1328 of SPAR is necessary for full-length SPAR
to bind to the PBD of Plk2.
We tested whether the Plk2-PBD interaction with SPAR re-
quires phosphorylation of ser-1328. In pull-down experiments, a
nonphosphorylated peptide comprising amino acids 1322–1335
of SPAR (‘‘S1328 peptide,’’ highlighted in gray in Figure 2A) cou-
pled to agarose beads failed to precipitate GST-PBD expressed
in bacteria (Figure 2D). The same peptide phosphorylated on
ser-1328 (‘‘pS1328 peptide’’) efficiently pulled down the PBD
fusion protein (Figure 2D). Thus, the PBD of Plk2 binds specifi-
cally to a peptide motif in SPAR centered on ser-1328, and
only when ser-1328 is phosphorylated.
Phosphorylation of Serine 1328 Is Important
for Plk2-Mediated Degradation of SPAR
Overexpression of Plk2 and SPAR in heterologous cells results in
Plk2-mediated phosphorylation and degradation of SPAR (Pak
and Sheng, 2003). Here, we used a tetracycline-inducible (‘‘Tet
On’’) promoter system to turn on the expression of Plk2 in
HEK293 cells also expressing SPAR from a constitutive pro-
moter. Following application of doxycycline (100 ng/ml), wild-
type SPAR was lost over the course of a few hours (presumably
degraded) with rising expression of wild-type Plk2 (Figure 3A,
quantified in 3B). Induction of a kinase-dead mutant of Plk2
[K.D. Plk2(K108M)] failed to cause degradation of SPAR (Figures574 Neuron 58, 571–583, May 22, 2008 ª2008 Elsevier Inc.3A and 3B). Mutations in the PBD of Plk2 at either trp-504
[Plk2(W504F)] or at his-626 and lys-628 [Plk2(H626A K628M)]
(two residues responsible for phospho-dependent binding of the
PBD [Elia et al., 2003b]), also prevented degradation of SPAR by
Plk2. Most importantly, the SPAR mutant defective in PBD bind-
ing [SPAR(S1328A)] was poorly degraded by wild-type Plk2 (Fig-
ures 3A and 3B). Thus, ser-1328 of SPAR and an intact PBD of
Plk2 are critical for Plk2-mediated degradation of SPAR, most
likely because interaction of the PBD with phosphorylated
ser-1328 is required for Plk2 recruitment to this target.
CDK5 Is a ‘Priming’ Kinase for SPAR ser-1328
To study more directly SPAR phosphorylation on ser-1328, we
raised phospho-specific antibodies against the pS1328
phosphopeptide (see Figure 2A). The affinity-purified antibody
(‘‘a-pS1328SPAR’’) recognized the phosphorylated S1328
peptide on slot blots, but not the unphosphorylated peptide
(Figure 4A). On western blots, a-pS1328SPAR detected a signal
from wild-type myc-tagged SPAR expressed in HEK293 cells,
but not myc-SPAR(S1328A) (Figure 4B, compare lanes 1–6 with
lanes 7–12). Collectively, these data indicate thata-pS1328SPAR
specifically recognizes SPAR phosphorylated on ser-1328.
Because ser-1328 precedes a proline residue (-S-S1328-P-R-
S-), we supposed that a proline-directed kinase is responsible
for phosphorylating this residue in SPAR. We tested drug
inhibitors of several proline-directed kinases by applying them
to HEK293 cells overexpressing myc-tagged SPAR. Inhibitors
of the MAP kinases p38 (SB-202190, 5 mM), JNK (SP-600125,
20 mM), or Erk, through its upstream activator MEK (PD-98059,
50 mM), had no effect on ser-1328 phosphorylation of SPAR, as
measured by immunoblotting with a-pS1328SPAR (Figure 4C,
quantified in 4D). Roscovitine (10 mM), a CDK5 inhibitor that can
Neuron
CDK5 and Plk2 in Synaptic Scalingalso block CDK1 and CDK2 at this concentration (Meijer et al.,
1997), significantly decreased thea-pS1328SPAR signal (Figures
4C and 4D).
To test whether neuron-specific CDK5 can phosphorylate ser-
1328 of SPAR, we coexpressed SPAR with CDK5 and its activa-
tor p35 in HEK293 cells; ser-1328 phosphorylation was strongly
enhanced (Figure 4B, lane 3; quantified in 4D). No effect on SPAR
ser-1328 phosphorylation was observed with a kinase-dead
CDK5 construct (‘‘CDK5-DN,’’ carrying an asp-144-to-asn muta-
tion [Nikolic et al., 1996]) or with constitutively active forms of
JNK1 or MEK1 (an upstream activator of Erk) (Figure 4B, quanti-
fied in 4D). KN-93 (5 mM), an inhibitor of CaMKII, had no effect on
ser-1328 phosphorylation (Figures 4C and 4D). These results are
consistent with motif predictions (Scansite) (Obenauer et al.,
2003), in which the sequence surrounding ser-1328 scored high-
est as a CDK5 phosphorylation motif.
Is endogenous SPAR phosphorylated on ser-1328 in neurons?
On immunoblots of rat hippocampal extracts, a-pS1328SPAR
detected a band of molecular weight similar to that of
recombinant SPAR (Figure 5A, where ‘‘R’’ denotes lanes loaded
with recombinant SPAR expressed in HEK293 cells). This
band was ‘‘quenched’’ by competition with excess of the phos-
pho-S1328 peptide, but not the unphosphorylated peptide
(Figure 5A, lanes 4 and 3). In addition, treatment of the mem-
branes with calf intestinal phosphatase (CIP) eliminated the
Figure 3. Intact PBD and ser-1328 Are Re-
quired for Plk2-Dependent Degradation of
SPAR
(A) HEK293 cells were triple transfected with myc-
tagged SPAR (wild-type or mutant, as indicated)
driven by constitutive CMV promoter, myc-tagged
Plk2 (WT or mutant, as indicated) driven by tetra-
cycline-responsive promoter, and pTET-On vector
driving reverse tetracycline-responsive transcrip-
tional activator (rtTA). After doxycycline treatment
(DOX, 100 ng/ml) for the indicated time to induce
Plk2 expression, cells were immunoblotted for
myc.
(B) Quantification of SPAR levels (mean ± SEM)
from multiple experiments performed as in (A).
n = 6 (WT SPAR + WT Plk2), n = 7 (WT SPAR +
Plk2[H626A K628M]), n = 5 (SPAR[S1328A] + WT
Plk2]), n = 8 (WT SPAR + Plk2[W504F]), n = 4
(WT SPAR + K.D. Plk2[K108M]), *p < 0.05, **p <
0.01 for WT SPAR + WT Plk2 compared to all other
combinations of SPAR and Plk2 constructs at the
indicated DOX treatment time points, one-way
ANOVA.
a-pS1328SPAR signal, while the signal
from a C-terminal SPAR antibody per-
sisted (Figure 5A, lanes 7–12). We con-
clude that a-pS1328SPAR specifically
detects phosphorylated SPAR in neu-
rons. Unfortunately, the a-pS1328SPAR
phosphoantibodies gave no significant
signal by immunocytochemistry of
cultured neurons.
SPAR was phosphorylated on ser-1328 in cultured corti-
cal neurons (DIV12), as detected by immunoblotting with
a-pS1328SPAR (Figure 5B). As in heterologous cells, the
a-pS1328SPAR signal in neurons was reduced by application of
the CDK5 inhibitor roscovitine for either 2 hr (data not shown) or
for 12–18 hr (Figure 5B, compare lanes 2 and 4 to lanes 1 and 3,
respectively). Inhibitors of JNK (SP-600125), MEK (PD-98059),
p38 (SB-202190), or CaMKII (KN-93) had no effect on phospho-
ser-1328 SPAR levels in neurons (Figure 5B, lanes 5–12).
To test whether endogenous CDK5 activity affects SPAR ser-
1328 phosphorylation, we infected cultured cortical neurons with
HSV virus driving expression of GFP alone or GFP together
with the CDK5 activator p35. Compared with control infection
with GFP alone, cortical cultures infected with p35 + GFP showed
a significant increase in endogenous SPAR ser-1328 phosphor-
ylation (Figure 5C). Together with the pharmacological data
(Figure 5B), these results show that a subpopulation of SPAR
is phosphorylated on ser-1328 in neurons and that this phos-
phorylation is enhanced by CDK5.
CDK5 activity is stimulated by Ab peptide (Alvarez et al., 2001;
Town et al., 2002), a proteolytic product of the amyloid precursor
protein (APP) that is implicated in the pathogenesis of Alz-
heimer’s disease (Walsh and Selkoe, 2004). We found that over-
night (15 hr) treatment with soluble Ab(1-40), but not the reverse
peptide Ab(40-1), elevated the phosphorylation of ser-1328 onNeuron 58, 571–583, May 22, 2008 ª2008 Elsevier Inc. 575
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CDK5 (Figure S2).
CDK5 Activity Promotes Degradation of SPAR
We showed that the SPAR(S1328A) mutant is protected from
degradation by Plk2 in HEK293 cells, presumably because it
cannot be phosphorylated at its PBD-binding site and thus can-
not interact with the Plk2-PBD (see Figure 3). We tested this
hypothesis further by repeating the same SPAR degradation
assay in the presence of roscovitine, which reduced basal phos-
phorylation of SPAR ser-1328 in HEK293 cells (see Figures 4C
and 4D). In the absence of roscovitine, doxycycline induced
the expression of Plk2 and concomitant degradation of SPAR
(Figure 6A). SPAR degradation was impaired by treatment of
the cells with roscovitine (Figure 6A). Our results support the
idea that CDK5 activity promotes SPAR degradation by ‘‘prim-
ing’’ phosphorylation of ser-1328 in the Plk2-PBD-binding site.
Overexpression of Plk2 promotes SPAR degradation in neu-
rons (Pak and Sheng, 2003). Because CDK5 regulates neuronal
SPAR ser-1328 phosphorylation (Figures 5B and 5C), we
wondered whether CDK5 activity contributes to SPAR degrada-
tion in neurons as well. Indeed, cultured hippocampal neu-
rons (DIV21–28) treated with roscovitine for 12–18 hr showed
increased endogenous SPAR levels by immunocytochemistry
(Figure 6B, quantified in 6C). Interestingly, the enhancement in
SPAR staining intensity was greatest in dendritic regions close
to the cell body and insignificant in the most distal dendrites
(Figure 6C). This proximal-distal gradient is reminiscent of the
activity-induced pattern of Plk2 protein expression, which is
also highest in proximal dendrites and tapers off with distance
from the cell body, and of the graded effect of Plk2 induction
on dendritic SPAR levels (Pak and Sheng, 2003). Our result is
thus consistent with CDK5 stimulating the degradation of
SPAR in neurons via a Plk2-dependent mechanism.
To corroborate the pharmacological data, we transfected
DIV16 hippocampal neurons for 3 days with a GFP-tagged dom-
inant-negative CDK5 construct (GFP-CDK5-DN). Overexpres-
sion of GFP-CDK5-DN, but not wild-type GFP-CDK5, increased
SPAR immunostaining intensity relative to control cultures trans-
fected with GFP alone (Figure 6D, quantified in 6E). These results
imply that CDK5 activity promotes the loss of SPAR, thus sup-
porting the idea that endogenous CDK5 acts as a priming kinase
for the degradation of SPAR.
CDK5 and SPAR Participate in Homeostatic Plasticity
If CDK5 priming activity is important for Plk2-dependent func-
tions like degradation of SPAR, blocking CDK5 activity might
also interfere with synaptic scaling, which requires Plk2. We
therefore tested the effect of the dominant-negative CDK5 con-
struct (CDK5-DN) on mEPSCs. As expected, in untransfected
cells, 48 hr of PTX treatment caused a significant shift in the
cumulative distribution of mEPSC amplitudes toward smaller
values, as well as a significant drop in the mean mEPSC ampli-
tude, reflecting normal synaptic scaling (Figure 7A). Overexpres-
sion of CDK5-DN had a small nonsignificant effect on mean
mEPSC amplitude in the absence of PTX treatment, but it pre-
vented the reduction in mEPSC amplitude induced by PTX
(Figure 7A). These results show that CDK5 is required under con-
ditions of elevated activity for dampening synaptic strength and
thus for homeostatic plasticity. The effect of CDK5-DN is similar
to that of dominant-negative GFP-PBD and Plk2 RNAi (see Fig-
ure 1), consistent with the idea that CDK5 and Plk2 act in the
same pathway to mediate synaptic homeostasis. Further sup-
porting this notion, cells transfected with both CDK5-DN and
GFP-PBD showed a similar degree of disruption of synaptic scal-
ing as cells transfected with either construct alone (Figure 7A).
CDK5-DN had no effect on mEPSC frequency compared to
untransfected cells (data not shown).
Figure 4. Phosphorylation of SPAR
ser-1328 and Regulation by CDK5
(A) ‘‘Slot blots’’ showing specificity of the
a-pS1328SPAR phospho-antibody for the phos-
phorylated S1328 peptide. Peptides were bound
to nitrocellulose and immunoblotted with
a-pS1328SPAR.
(B) CDK5 enhances ser-1328 phosphorylation in
heterologous cells. Myc-tagged wild-type SPAR
or SPAR(S1328) was transfected into HEK293
cells with the indicated protein kinase constructs
or treated with roscovitine for 2 hr. SPAR was
immunoprecipitated with myc antibody and immu-
noblotted with a-pS1328SPAR followed by strip-
ping and reprobing with myc antibodies.
(C) CDK5 inhibitor roscovitine reduces SPAR ser-
1328 phosphorylation. HEK293 cells were trans-
fected with myc-SPAR and treated for 2 hr with
the indicated drugs, then immunoblotted with
a-pS1328SPAR, stripped, and reprobed with myc
antibodies.
(D) Quantification of data from (B) and (C), normal-
ized to control conditions from the same blot
(mean ± SEM). n = 5–6 for each condition, except
roscovitine (n = 11). *p < 0.05, **p < 0.01, com-
pared to control (100%), two-tailed t test.576 Neuron 58, 571–583, May 22, 2008 ª2008 Elsevier Inc.
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Phosphorylation in Neurons
(A) Phosphorylation of SPAR ser-1328 in rat hippo-
campus. Total hippocampal extracts were immu-
noblotted with either a-pS1328SPAR or SPAR an-
tibodies (upper row) and with PSD-95 or tubulin
antibodies, as indicated. The pS1328SPAR signal
was specifically eliminated by competition with
the phospho-S1328 peptide (lane 4), but not by
the unphosphorylated S1328 peptide (lane 3).
Calf intestinal phosphatase (CIP) treatment of the
membrane eliminated the pS1328SPAR signal
(lanes 7–10). ‘‘R’’ lanes were loaded with HEK293
cell extract expressing recombinant SPAR
protein.
(B) Ser-1328 SPAR phosphorylation in neurons
reduced by CDK5 inhibitor. Dissociated high-
density cortical cultures (DIV12) were treated for
12–18 hr with vehicle (DMSO) or roscovitine
(‘‘Ros,’’ 10 mM), SP-600125 (‘‘SP,’’ 20 mM), PD-
98059 (‘‘PD,’’ 50 mM), SB-202190 (‘‘SB,’’ 5 mM),
or KN-93 (‘‘KN,’’ 5 mM). Total cell lysates were im-
munoblotted with a-pS1328SPAR, then stripped
and reprobed with SPAR antibodies (left). Bar
graph (right) shows quantification of blots, normal-
ized to control conditions from the same blot
(mean ± SEM). n = 7–9 for each condition. ***p <
0.001, compared to control (100%), two-tailed t
test.
(C) Regulation of ser-1328 SPAR phosphorylation
in neurons by CDK5. High-density cortical (DIV12)
cultures were infected for 24 hr with HSV driving
expression of either GFP alone (lanes 1–4) or GFP
together with the CDK5 activator p35 (lanes 5–8).
Total cell lysates were immunoblotted with the in-
dicated antibodies (left) and quantified (mean ±
SEM, normalized to control GFP-infected cells)
(right). n = 16 for each condition, **p < 0.01,
Mann Whitney test.Does Plk2 dampen synaptic strength during homeostatic plas-
ticity through degradation of SPAR? To address this question,
we transfected cells with either WT SPAR or SPAR(S1328A),
which carries a mutation in the Plk2-binding site and is resistant
to degradation by Plk2 (see Figure 3). Neurons transfected with
either WT SPAR or SPAR(S1328A) showed a trend toward in-
creased mean mEPSC amplitude relative to untransfected cells,
but this effect did not reach statistical significance (Figure 7B).
mEPSC frequency was also unchanged in neurons transfected
with either WT SPAR or SPAR(S1328A) (data not shown). In
untransfected cells and cells transfected with WT SPAR, 48 hr
of PTX treatment caused a significant drop in mEPSC amplitude
(Figure 7B), consistent with normal homeostatic plasticity. In
contrast, cells transfected with SPAR(S1328A) failed to undergo
synaptic scaling in response to PTX treatment (Figure 7B). These
results thus link degradation of SPAR to Plk2-mediated synaptic
weakening during chronically elevated activity.
If Plk2-mediated degradation of SPAR contributes to down-
scaling of mEPSCs during elevated activity, knockdown of
SPAR expression by RNAi might mimic that effect. Indeed, cells
transfected with an RNAi construct targeting endogenous SPARshowed significantly diminished mEPSC amplitude compared to
untransfected cells and cells transfected with a control RNAi
construct against firefly luciferase (‘‘FF RNAi’’) (Figure 7C).
Together with the finding of impaired homeostasis in neurons
expressing SPAR(S1328A), these data suggest that activity-
dependent depletion of SPAR is an important mechanism for
synaptic weakening during homeostatic plasticity. A molecular
model of activity-dependent synaptic scaling based on these
results is shown in Figure 8.
DISCUSSION
Activity-Inducible Plk2 and Synaptic Scaling
Homeostatic plasticity has emerged as an important regulatory
mechanism for stabilizing the activity of neurons and circuits.
Among its proposed functions are prevention of epilepsy, bal-
ancing of excitation and inhibition, stabilization of neurons during
Hebbian plasticity, and regulation of spontaneous network activ-
ity during development (Davis, 2006; Gonzalez-Islas and
Wenner, 2006; Turrigiano, 2007).Neuron 58, 571–583, May 22, 2008 ª2008 Elsevier Inc. 577
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contribute to homeostasis following chronic reduction of neuro-
nal activity. Release of TNF-a from glia (Stellwagen and Malenka,
2006), regulation of the b to aCaMKII ratio (Thiagarajan et al.,
2002), BDNF (Rutherford et al., 1998), adenylyl cyclase 1
(Gong et al., 2007), and downregulation of the activity-inducible
Figure 6. CDK5 Promotes Degradation of SPAR
(A) Roscovitine prevents SPAR degradation by Plk2 in heterologous cells. HEK293 cells triple transfected with myc-tagged WT SPAR, tet-inducible myc-tagged
WT Plk2, and the pTET-On vector were immunoblotted (top) with myc antibodies after doxycycline treatment (as in Figure 3). HEK293 cells were treated with
either DMSO (‘‘vehicle’’) or roscovitine (10 mM), as indicated, for the final 8 hr before lysis. SPAR levels were quantified (mean ± SEM) and plotted as a function
of DOX induction time for DMSO and roscovitine treatment conditions (bottom). n = 5 (DMSO), n = 9 (roscovitine). *p < 0.05, curves are different, two-way ANOVA.
(B) Increased SPAR immunostaining in neurons following pharmacological inhibition of CDK5. Example of hippocampal neurons (DIV21–28) treated for 12–18 hr
with either roscovitine (10 mM) or vehicle (DMSO) and stained with SPAR antibodies to visualize endogenous SPAR protein. The boxed region is shown at higher
magnification below. Scale bar: 50 mm low magnification and 5 mm high magnification.
(C) Quantification of dendritic SPAR immunofluorescence intensity data from (B), plotted as a function of distance from the cell body (see Experimental Proce-
dures) (mean ± SEM). SPAR immunofluorescence intensity from both treatment conditions was normalized to the 10 mm distance of DMSO-treated neurons.
n = 18 cells (roscovitine), n = 16 cells (DMSO), **p < 0.01, ***p < 0.001, two-way ANOVA with post test.
(D) SPAR accumulation in neurons overexpressing dominant-negative CDK5 (GFP-CDK5-DN). DIV16 hippocampal neurons were transfected with GFP-tagged
CDK5(D144N) (‘‘GFP-CDK5-DN’’), WT GFP-CDK5, or GFP, fixed at DIV19, and stained with SPAR antibodies to visualize endogenous SPAR protein. The merge
of the two signals is shown in color. Scale bar: 50 mm (low magnification) and 5 mm (high magnification).
(E) Quantification of SPAR immunofluorescence intensity data from (D). Histograms (mean ± SEM) are normalized to neighboring untransfected neurons. n = 16
cells (all constructs), ***p < 0.001, GFP-CDK5-DN is significantly different than other conditions, one-way ANOVA.578 Neuron 58, 571–583, May 22, 2008 ª2008 Elsevier Inc.
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CDK5 and Plk2 in Synaptic ScalingFigure 7. CDK5 and SPAR Participate in
Homeostatic Plasticity
(A) CDK5 inhibitor impairs synaptic homeostasis
during heightened activity. Representative 5 s sam-
ple traces and average mEPSC event traces from
individual untransfected cells and cells transfected
with either GFP-tagged CDK5(D144N) (‘‘CDK5-
DN’’), or CDK5-DN together with GFP-PBD
(‘‘CDK5-DN + GFP-PBD’’), treated with either vehi-
cle (DMSO) or PTX for 48 hr, as indicated (left). Cu-
mulative distributions (top right) of mEPSC ampli-
tudes were generated from the first 100 events of
recorded cells from conditions as indicated.
‘‘Untr’’ is significantly different than ‘‘Untr + PTX’’
and ‘‘CDK5-DN,’’ p < 0.001; ‘‘CDK5-DN’’ is not sig-
nificantly different than ‘‘CDK5-DN + PTX,’’ p > 0.05;
Kolmogorov-Smirnov test. Bar graphs (bottom
right) show quantitation of mEPSC amplitude
(mean ± SEM). n = 17–19 cells per condition (left
bar graph); n = 11–16 cells per condition (right bar
graph); *p < 0.05, ***p < 0.001, Mann Whitney test.
(B) SPAR mutant resistant to Plk2 degradation pre-
vents synaptic scaling. Sample traces (left), cumu-
lative distributions (top right), and quantification of
mEPSC amplitude (mean ± SEM; bottom right)
from neurons transfected with wild-type SPAR or
SPAR(S1328A), and treated with PTX, as indicated,
**p < 0.01, Mann Whitney test. Cumulative distribu-
tion of ‘‘SPAR’’ is significantly different than ‘‘SPAR
+ PTX,’’ p < 0.001; ‘‘SPAR(S1328A)’’ is significantly
different than ‘‘SPAR(S1328A) + PTX,’’ p < 0.01;
Kolmogorov-Smirnov test. n = 12–14 cells per
condition.
(C) RNAi knockdown of SPAR weakens synapses.
Representative mEPSC traces from untransfected
cells and cells transfected with SPAR RNAi or neg-
ative control firefly luciferase RNAi (‘‘FF RNAi’’) (left).
Cumulativedistributionplot (middle)andbargraphs
of mEPSC amplitude (mean ± SEM; right) quantify
the effect of SPAR RNAi knockdown. Cumulative
distribution of ‘‘SPAR RNAi’’ is significantly different
than ‘‘Untrans’’ and ‘‘FF RNAi,’’ p < 0.001; ‘‘FF
RNAi’’ is not significantly different than ‘‘Untrans,’’
p > 0.05; Kolmogorov-Smirnov test. n = 11–15 cells
per condition, ***p < 0.001, Mann Whitney test.gene arc/arg3.1 (Shepherd et al., 2006) were shown to be impor-
tant for the upregulation of mEPSC amplitude and/or frequency
following prolonged inactivity in cultured neurons. Hippocampal
cultures from arc/arg3.1 knockout mice continued to display sig-
nificant downscaling of mEPSCs in response to chronic hyper-
activity induced by the GABAA blocker bicuculline, leading the
authors to conclude that mechanisms apart from Arc/Arg3.1
are likely to be important for the weakening of synapses following
long-term increases in activity (Shepherd et al., 2006). Our study
points to Plk2 in this role.
Key questions in homeostatic plasticity include the following.
What are the molecules involved in sensing perturbations from
a set point? And how are these transduced into a negative-feed-
back response appropriate for the type and magnitude of the ini-
tial perturbation? Postsynaptic calcium levels are positively cor-
related with neuronal activity (Goldberg and Yuste, 2005; Ross,1989), and calcium sits atop numerous biochemical signaling
cascades affecting gene expression (Burgoyne et al., 2004).
The induction of Plk2 protein by activity takes many hours and
involves calcium entry through voltage-gated calcium channels
and/or NMDA receptors, as well as activation of the calcium-cal-
modulin-dependent protein phosphatase PP2B/calcineurin (Pak
and Sheng, 2003). Thus, intracellular calcium elevation and a de-
layed rise in Plk2 expression provide a means of sensing pro-
longed increases in ambient network activity. Because it phos-
phorylates key substrate(s) that regulate synapse morphology
and function, the Plk2 protein kinase can then transduce the el-
evated activity into a negative-feedback response that dampens
synaptic strength. Thus, Plk2 provides a link between sensing
elevated activity and the homeostatic feedback response.
Our findings point to the degradation of SPAR as an important
mechanism of Plk2-mediated weakening of synapses. RNAiNeuron 58, 571–583, May 22, 2008 ª2008 Elsevier Inc. 579
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strength; more significantly, synaptic homeostasis is disrupted
when a SPAR mutant resistant to Plk2-mediated degradation
is overexpressed in neurons. Degradation of the postsynaptic
RapGAP SPAR by Plk2 would be expected to enhance the activ-
ity of postsynaptic Rap GTPases, which are known to depress
synaptic transmission (Huang et al., 2004; Zhu et al., 2002,
2005) and cause thinning of spines (Fu et al., 2007; Xie et al.,
2005). In addition to effects on Rap signaling, SPAR may also
promote spine morphogenesis and synaptic function via its scaf-
folding or actin-binding properties (Pak et al., 2001).
CDK5 Priming and Regulation of Plk2 Function
Degradation of SPAR by Plk2 requires phosphorylation of SPAR
on ser-1328. We identify CDK5 as the likely proline-directed
kinase that ‘‘primes’’ this site, generating a phosphomotif that
is specifically recognized by the PBD of Plk2. Inhibition of CDK5
led to decreased ser-1328 phosphorylation and increased SPAR
protein levels in neurons. More importantly, CDK5 activity was
required for suppression of mEPSC amplitude during elevated
network activity. These results are consistent with CDK5 playing
a critical role in synaptic homeostasis.
We further note that ser-1328 lies in SPAR’s Act2 domain,
which interacts with the actin cytoskeleton (Pak et al., 2001).
We speculate that in addition to priming SPAR for phosphoryla-
tion and degradation by Plk2, ser-1328 phosphorylation might
release SPAR from association with actin. The latter event might
facilitate release of SPAR from the PSD and subsequent interac-
tion with Plk2.
The regulation of CDK5 by synaptic activity is poorly under-
stood. Currently, CDK5 activity is believed to be mainly regulated
by the abundance of its activator subunits p39 and p35. Treat-
ment with excitotoxic levels of glutamate increases CDK5 activ-
ity through calpain-mediated cleavage of p35 to p25 (Lee et al.,
2000), whereas lower levels of glutamate (%0.1 mM) seem to
reduce CDK5 activity by proteasomal degradation of p35 (Hoso-
kawa et al., 2006; Wei et al., 2005). It would be interesting to de-
fine in more detail the regulation of CDK5 by synaptic activity,
because local modulation of CDK5 could impart local priming
of SPAR, leading to synapse-specific actions of Plk2.
The amyloid-b peptide (Ab) can also induce the conversion of
p35 to p25 (Lee et al., 2000) and activate CDK5 (Roselli et al.,
Figure 8. Model for Plk2-Dependent Synaptic Scaling
Priming phosphorylation of SPAR ser-1328 by CDK5 recruits activity-induced
Plk2 to SPAR, followed by phosphorylation of SPAR by Plk2, ubiquitination-
degradation of SPAR, and synaptic weakening.580 Neuron 58, 571–583, May 22, 2008 ª2008 Elsevier Inc.2005; Town et al., 2002). Consistent with these studies, we found
that prolonged exposure of neurons to Ab resulted in an increase
in SPAR-ser-1328 phosphorylation. Soluble Ab, which is proba-
bly an important toxic mediator in Alzheimer’s disease (Mattson,
2004; Walsh and Selkoe, 2004), inhibits synaptic transmission at
least in part via endocytic removal of AMPARs (Hsieh et al., 2006;
Kamenetz et al., 2003). Our study introduces a mechanism by
which Ab could cause weakening and loss of synapses—
namely, increased phosphorylation of SPAR by CDK5, priming
SPAR for degradation by Plk2 during periods of heightened
activity.
The fact that CDK5 phosphorylation generates a Polo-box-
binding site in SPAR raises the intriguing possibility that Plk2
function in neurons can be controlled by the regulated recruit-
ment of Plk2 to phosphorylated -S-S/T-P- motifs on SPAR and
other targets. Plk2 function would then require the coincidence
of two conditions—prolonged elevated neuronal activity to in-
duce Plk2 protein expression as well as the availability of primed
binding sites for the PBD—thus allowing for spatial and temporal
refinement in the control of Plk2 activity.
In the cell cycle, priming kinases like cdc2/CDK1 regulate the
availability of Plk-binding sites to ensure that the many functions
of mitotic Plks are carried out with required precision in time and
subcellular location (van de Weerdt and Medema, 2006). Simi-
larly, precise regulation in neurons might allow the specific
recruitment of Plk2 to synapses that have been ‘‘tagged’’ by the
phosphorylation of SPAR ser-1328 or other PBD-binding sites.
Such synapse-specific tagging of target proteins could arise
from localized activation of CDK5 (or other priming kinases),
though this remains to be shown for CDK5. In this context, it is
noteworthy that Plk2 protein levels are higher in proximal than
in distal dendrites after 18–24 hr of PTX induction (Pak and
Sheng, 2003).
How might this proximal-to-distal gradient be reconciled with
the view that homeostatic plasticity acts globally in neurons?
One possibility is that the gradient seen by Pak and Sheng
(2003) forms only during the early phase of induction of Plk2
and is dissipated by 48 hr, when most electrophysiological mea-
surements of synaptic scaling (including our experiments here)
are performed. Alternatively, homeostatic synaptic plasticity may
not be as global as presumed (see Turrigiano, 2007). Indeed, re-
cent studies have suggested the existence of ‘‘local’’ homeo-
static mechanisms occurring at the level of individual dendritic
segments (Ju et al., 2004; Sutton et al., 2006) or even individual
synapses (Hou et al., 2008). An important role of homeostatic
plasticity is the stabilization of neuronal firing rates (Burrone
and Murthy, 2003), which would be predicted to be most effec-
tive if concentrated on dendritic segments closest to the soma.
Thus, there may be a cellular logic to exerting a proximal-to-dis-
tally graded mechanism of homeostatic change.
EXPERIMENTAL PROCEDURES
DNA Constructs
GFP-PBD was generated by PCR of the Plk2-PBD (aa 332–682) followed by
insertion into a b-actin-driven GFP vector. rtTA-responsive Plk2 was generated
by PCR of myc-tagged full-length Plk2 from pGW1, followed by insertion into
pTRE (Clontech). For Plk2 RNAi, the following siRNA sequence was cloned into
pSUPER (Brummelkamp et al., 2002): 50-GCATAAGAGAAGCAAGATA-30. The
Neuron
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TAAGTA-30 and was a gift from Eunjoon Kim (KAIST). Site-directed mutagene-
sis was performed using ‘‘Quickchange’’ (Stratagene), and all constructs were
verified by DNA sequencing. GFP-CDK5, GFP-CDK5-DN, and GFP-p35 were
gifts from Li-Huei Tsai. The following constructs have been described: Kv1.4
C terminus in pBHA, and PSD-95 PDZ 1/2 in pGAD10 (Kim et al., 1995), Act2
in pBHA, Plk2-PBD in pGAD, myc-tagged SPAR in pGW1, GST-tagged Plk2-
PBD in pGEX (Pak and Sheng, 2003; Pak et al., 2001), a-actinin-2 (A2.10) in
pGAD (Wyszynski et al., 1997). siRNA sequences for SPAR (50-CCGCCTG
AAGTCTCTGATTAA-30 ) and firefly luciferase (50-CCGCCTGAAGTCTCTGAT
TAA-30) in pENTR-Mir U6 vectors were gifts from Wade Harper (Harvard).
Antibodies, Ab(1-40), and Drugs
Phospho-specific a-pS1328 SPAR antibodies were generated by immunizing
rabbits (Covance Research Products) with a SPAR peptide corresponding to
residues 1323–1335, in which S1328 was phosphorylated. Phospho-anti-
bodies were purified first by negative selection over a column of covalently
attached unphosphorylated peptide, followed by binding to a column of phos-
phorylated peptide. Polyclonal GKBD-SPAR antibodies (used in Figures 5B,
5C, and 6) were generated by immunizing rabbits with purified MBP-GKBD
fusion protein.
The polyclonal C-SPAR antibody (used in Figure 5A) has been described
(Pak et al., 2001). Mouse monoclonal PSD-95 antibody K28/43 was a gift
from J. Trimmer (UC Davis); rabbit polyclonal p25/p35 antibody was a gift
from Li-Huei Tsai (MIT). The following antibodies were purchased from com-
mercial sources: mouse monoclonal myc antibody (9E10), myc agarose con-
jugate, polyclonal GST (Z-5) antibody (Santa Cruz Biotechnology), monoclonal
a-tubulin (B-5-1-2) antibody (Sigma), polyclonal GFP antibody (MBL). Ab(1-40)
and Ab(40-1) (American Peptide Company) were solubilized and used as de-
scribed (Roselli et al., 2005). Drugs were purchased from Sigma.
Yeast Two-Hybrid and Virus Preparation
Two-hybrid assays were performed using the yeast strain L40 harboring b-gal
and HIS3 reporters, as described (Niethammer and Sheng, 1998).
Plk2 was cloned into a modified pSinRep5 vector (Invitrogen) containing
GFP preceded by an IRES2 internal ribosomal entry site. Sindbis virus was pre-
pared according to manufacturer guidelines (Invitrogen). Briefly, DNA tem-
plates were transcribed using an in vitro transcription kit (Ambion) and then
electroporated into BHK cells. 24–36 hr posttransfection, the supernatant
was harvested and used for hippocampal culture infection by directly pipetting
virus into growth medium. Recordings were performed 24 hr postinfection
under visual guidance of the GFP signal.
HSV packaged with p35 and/or GFP was a gift from Li-Huei Tsai (MIT).
HEK293 Transfection, Doxycycline Time Course,
Immunoprecipitation, and GST-‘‘Pull-Downs’’
HEK293 cells were transfected using Lipofectamine (Invitrogen). For GST-pull-
down and immunoprecipitation assays, cells were lysed in RIPA buffer, and
lysates centrifuged at 15,000 3 g for 30 min. Myc-antibody (9E10)-coupled
agarose, or GST, GST-tagged Plk2-PBD, or GST-tagged Plk2-PBD(W504F)
coupled to glutathione Sepharose, were mixed with supernatants for 3 hr at
4C. After washing five times in RIPA buffer, immunoprecipitates were ana-
lyzed by immunoblotting. For doxycycline time course experiments, doxycy-
cline was applied the day after transfection for the indicated times.
Peptide Precipitation Experiments
E. coli (BL21) expressing GST-PBD were lysed by sonication in ice-cold PBS,
followed by addition of Triton X-100 (1% final concentration) and shaking at
4C for 20 min. Lysates were centrifuged at 15,0003 g for 30 min, and super-
natants were then incubated with agarose beads coupled to either the phos-
phorylated pS1328 peptide or the unphosphorylated S1328 peptide for 3 hr
at 4C under gentle agitation. Peptide coupling was performed using the Sul-
foLink kit (Pierce). After washing in lysis buffer (PBS, 1% TX-100), precipitated
protein was analyzed by coomassie staining and immunoblotting.Dissociated Neuron Culture, Transfection, and Immunostaining
Hippocampal or cortical cultures were prepared and cultured from E19
Sprague Dawley rats as previously described (Pak et al., 2001). Briefly,
150–200 cells mm2 (hippocampal culture) or 1000 cells mm2 (cortical culture)
were plated on 19 mm coverslips coated with 30 mg/ml poly-D-lysine and
2 mg/ml laminin. Transfections of hippocampal cultures were performed with
Lipofectamine 2000 (Invitrogen) at DIV16–19, and cells were either recorded
3–4 days later or fixed 3 days later in 1% formaldehyde, 4% sucrose in PBS
for 2 min at room temperature followed by20C MetOH for 10 min for staining
of endogenous proteins. Antibodies were applied in GDB buffer (0.1% gelatin,
0.3% TX-100, 450 mM NaCl, 32% 0.1M Phosphate buffer [pH 7.4]).
Electrophysiology
Electrophysiological recordings of hippocampal neurons were performed
3-4 days after transfection in bath solution containing (in mM): 119 NaCl, 2.5
KCl, 2.8 CaCl2, 2 MgCl2, 26 NaHCO3, 1 NaH2PO4, 11 glucose, 0.1 picrotoxin,
gassed with 5% CO2/95% O2 at pH 7.4. Recordings were carried out at
30-34C. TTX (1 mM) was added to block action potentials. Whole-cell record-
ings were made under visual guidance with the aid of IR-DIC optics. Cells were
recorded from for roughly 5 min to obtain at least 100 events/cell.
Pipettes (2.5–4 MU) were filled with an internal solution containing (in mM):
115 cesium methanesulfonate, 20 CsCl, 10 HEPES, 2. 5 MgCl2, 4 ATP diso-
dium salt, 0.4 GTP trisodium salt, 10 sodium phosphocreatine, and 0.6
EGTA, at pH 7.25.
Whole-cell voltage-clamp recordings were made using a Multiclamp 700A
amplifier (Axon Instruments). Current signals were filtered at 2 kHz and digi-
tized at 10 kHz with a Digidata 1322A (Axon Instruments). Analysis of record-
ings was performed using Clampfit software (Axon Instruments). Recordings
and quantitation were performed blind to experimental conditions.
Imaging and Quantitation
Images were acquired using an LSM510 confocal system with an oil-immer-
sion 63X objective (NA 1.4, Zeiss). Confocal Z-series image stacks encom-
passing entire dendrite segments were analyzed using MetaMorph software
(Universal Imaging Corporation). For measurements of SPAR immunofluores-
cence intensity as a function of distance from the soma, concentric circles
increasing in 10 mm steps were traced around the soma, and three to four den-
dritic segments of 90 mm were analyzed from thresholded images. For each
condition, integrated SPAR immunofluorescence intensity levels from distinct
dendrites for each distance (i.e., dendritic segments bound by the same two
circles) were first grouped and averaged per neuron. Means from several neu-
rons were then averaged to obtain a population mean and normalized to the
10 mm population mean in vehicle-treated controls (presented as mean ±
SEM). SPAR immunofluorescence intensity levels from transfected cells are
from thresholded images and represent integrated intensity measurements
per unit length of dendrite. SPAR immunofluorescence intensity levels from
three to four dendritic segments of 90 mm were collected and averaged per
neuron. Average SPAR immunofluorescence intensities for each transfected
cell were normalized to values obtained from nearby untransfected cells and
then averaged with cells transfected with the same construct to obtain a pop-
ulation mean (presented as mean ± SEM). All imaging and quantitation were
performed blind to experimental conditions.
Statistical Analysis
Statistical Methods are described in the Figure Legends.
SUPPLEMENTAL DATA
The Supplemental Data for this article, which include a table and figures, can
be found online at http://www.neuron.org/cgi/content/full/58/4/571/DC1/.
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